IN THE CLAIMS:

Please amend claims 3, 5, 7, 9, 11-14, 16, 27, 29, 31, 33, 35-38, 40, 50, 52, 54, 56, 58-61, 73, 75, 77, 79, 81-84, 100-102, 104, 113, 126, 139 to read as follows:

B1 SUB C1)

3. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the primary effector molecules is a TNF family member.

B2 SUB C2)

5. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

B3 SUB C3)

7. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

B4 SUB C4)

9. (Amended) The attenuated tumor targeted bacteria of claim 2, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

B5

11. (Amended) The attenuated tumor targeted bacteria of claim 2, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2, or PMT.

12. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

SUB C5)

13. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the secondary effector molecules is an immunomodulating agent, an anti-tumor protein, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

14. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein the attenuated tumor-targeted bacteria is *Salmonella*.

SUB C6)
B6

16. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the secondary effector molecule is a bacteriocin release factor (BRP).

B7 SUB C7)

27. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is a TNF family member.

B8 SUB C8)

29. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

B9 SUB C9)

31. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

B10 SUB C10)

33. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

B11

35. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2, or PMT.

36. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

SUB C11)

37. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the secondary effector molecules is an immunomodulating agent, an anti-tumor protein, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

38. (Amended) The pharmaceutical composition of claim 26, wherein the attenuated tumor-targeted bacteria is *Salmonella*.

B12 SUB C12)

40. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

B13 SUB C13)

50. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is a TNF family member.

B14 SUB C14)

52. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

B15 SUB C15)

54. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

B16 SUB C16)

56. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

58. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2 or PMT.

B17 SUB C17)

59. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

B18 SUB C17)

60. (Twice Amended) The method of claim 49, wherein at least one of the secondary effector molecules is an anti-tumor protein, an immunomodulating agent, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

B19 SUB C17)

61. (Amended) The method of claim 49, wherein the attenuated tumor-targeted bacteria is *Salmonella*.

B20

73. (Amended) The method of claim 72, wherein at least one of the primary effector molecules is a TNF family member.

B21

75. (Amended) The method of claim 72, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

B22

77. (Amended) The method of claim 72, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

B23

79. (Amended) The method of claim 72, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

B24

81. (Amended) The method of claim 72, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2, or PMT.

82. (Amended) The method of claim 72, wherein the primary effector molecule is derived from an animal, plant, bacteria, or virus.

83. (Amended) The method of claim 72, wherein at least one of the secondary effector molecules is an immunomodulating agent, an anti-tumor protein, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

84. (Amended) The method of claim 72, wherein the attenuated tumor-targeted bacteria is *Salmonella*.

NE

100. The attenuated tumor targeted bacteria of claim 2, wherein at least of one of the secondary effector molecules is a release factor.

B25

101. (Amended) The attenuated tumor targeted bacteria of claim 13, wherein the antisense molecule is double-stranded or single-stranded DNA, double-stranded or single-stranded RNA, or a triplex molecule.

SUB C18)

102. (Amended) The attenuated tumor targeted bacteria of claim 13, wherein the anti-tumor protein is a ribosome inactivating protein.

B26

SUB C19)

104. (Amended) The attenuated tumor targeted bacteria of claim 13, wherein the pro-drug converting enzyme is cytochrome p450 NADPH oxidoreductase.

B27

SUB C20)

113. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the secondary effector molecules is a release factor.

B28

SUB C21)

126. (Amended) The method of claim 49, wherein at least one of the secondary effector molecules is a release factor.